Yes, policy changes are poised to significantly expand Alzheimer’s screening nationwide. The Alzheimer’s Screening and Prevention (ASAP) Act, introduced in both the House and Senate in November 2025 with bipartisan support, creates a pathway for Medicare coverage of FDA-approved blood biomarker screening tests—a critical shift that could accelerate detection by years. Until now, Medicare has been unable to cover new screening tests until they receive explicit Congressional authorization or a recommendation from the U.S. Preventive Services Task Force, creating a gap of years or even decades between when the FDA approves a test and when Medicare patients can access it.
The ASAP Act aims to close that gap, potentially making advanced Alzheimer’s blood tests available to millions of older adults. Beyond legislative action, Congress has also approved $100 million in new funding for Alzheimer’s and dementia research, plus $41.5 million for the CDC’s Building Our Largest Dementia Infrastructure (BOLD) program to strengthen state and community capacity for early detection. These changes reflect a fundamental shift in how the United States approaches Alzheimer’s disease: from responding to symptoms after they’ve appeared to identifying at-risk individuals years before cognitive decline becomes apparent. This article explores the policy changes driving this transformation, the new blood tests now available, what Medicare coverage could mean for patients, and how early detection is changing treatment possibilities.
Table of Contents
- What Is the ASAP Act and Why Does It Matter?
- How Blood-Based Biomarkers Are Changing Early Detection
- FDA Approvals and What They Mean for Patients
- Medicare Coverage and Financial Access
- Clinical Benefits and Treatment Implications
- Federal Funding and Infrastructure Expansion
- The Future of Alzheimer’s Prevention and Early Detection
- Conclusion
- Frequently Asked Questions
What Is the ASAP Act and Why Does It Matter?
The Alzheimer’s Screening and Prevention (ASAP) Act (H.R. 6130 in the House and S. 3267 in the Senate) represents a direct response to a structural problem in Medicare’s preventive care system. Under current law, Medicare can only cover preventive services that have been explicitly authorized by Congress or recommended by the U.S. Preventive Services Task Force (USPSTF).
This creates a long waiting period: a test can be FDA-approved, tested in clinical settings, and validated by the medical community, yet Medicare still cannot cover it without jumping through bureaucratic hoops. For Alzheimer’s blood biomarkers, this delay has been particularly costly, since early detection offers the greatest opportunity to slow cognitive decline. The ASAP Act changes this by allowing Medicare to cover FDA-approved blood-based biomarker tests for Alzheimer’s detection without waiting for additional Congressional action or USPSTF recommendations. This is significant because it removes one of the largest barriers to widespread screening: the inability of beneficiaries to access tests through their primary insurance. Proponents argue this accelerated pathway is especially important for Alzheimer’s, where the window for early intervention is narrow and effective treatments exist for eligible patients. The legislation has been introduced with support from members of both parties, suggesting it has genuine potential to advance through Congress.
How Blood-Based Biomarkers Are Changing Early Detection
Blood biomarker tests represent a major breakthrough in Alzheimer’s diagnosis because they can detect the biological changes associated with the disease—amyloid and tau protein buildup—in the bloodstream, years before symptoms appear. This is transformative because it means cognitive decline can potentially be identified and addressed before patients or their families notice memory problems. Historically, Alzheimer’s diagnosis required PET imaging, MRI, or cerebrospinal fluid testing, all of which are expensive, time-consuming, or invasive. Blood tests sidestep these barriers by being simple, affordable, and suitable for routine screening in primary care settings. However, it’s important to note that a positive blood biomarker test does not mean a person currently has Alzheimer’s disease or will definitely develop symptoms.
These tests show biological changes that are associated with increased risk. The distinction matters: a positive result means someone has evidence of amyloid or tau buildup, which warrants closer monitoring and potentially preventive treatment, but doesn’t guarantee cognitive decline. A person could carry these biomarkers for years or decades without developing dementia. Conversely, negative blood biomarker tests provide strong reassurance—they carry a 97.9% negative predictive value, meaning if the test is negative, the risk of current Alzheimer’s pathology is very low. This allows clinicians to confidently rule out Alzheimer’s-related biological changes in many patients, reducing unnecessary further testing and anxiety.
FDA Approvals and What They Mean for Patients
Two major FDA-approved blood biomarker tests have recently become available, making nationwide screening more practical. Fujirebio’s Lumipulse G β-Amyloid Ratio Test received FDA approval in March 2025, becoming one of the first blood tests cleared to aid in the assessment of Alzheimer’s disease. That same year, Roche Diagnostics’ Elecsys pTau181 Plasma Test was FDA-cleared in October 2025, specifically indicated as an aid for initial assessment of Alzheimer’s disease in primary care settings. Both tests were developed to work within primary care workflows, not just in specialized memory clinics, which is crucial for expanding access.
The availability of multiple approved tests is important because it creates options and promotes competition that can drive down costs and improve quality. A patient whose primary care doctor has access to one test might have access to a different test, depending on what their healthcare system has implemented. This variety also means that clinicians can choose the test that best fits a patient’s situation—some tests measure amyloid burden, others measure tau phosphorylation, and some measure combined pathology. The goal is to identify individuals with evidence of Alzheimer’s pathology who might benefit from early interventions, such as anti-amyloid monoclonal antibodies or other emerging treatments. Without access to these tests, many at-risk individuals never receive the opportunity for early treatment.
Medicare Coverage and Financial Access
The Centers for Medicare & Services (CMS) has established a reimbursement rate of $130 per test for beta-amyloid and tau biomarker tests, a significant acknowledgment of their clinical value. This reimbursement rate is crucial because it determines whether primary care practices, hospitals, and diagnostic laboratories will offer these tests to Medicare beneficiaries. At $130 per test, the financial incentive exists for widespread implementation, though it remains to be seen whether this will be the standard across all tests and all providers. The financial advantage of blood biomarkers over traditional diagnostic methods is stark.
These tests cost 80-90% less than PET imaging, MRI, or other imaging-based approaches to diagnosis, yet deliver comparable diagnostic accuracy. For a Medicare beneficiary who might otherwise need to wait months for a specialist appointment and pay out-of-pocket for imaging, a simple blood test available in primary care is transformative. However, coverage varies by insurance type: Medicare beneficiaries may have different access than Medicaid enrollees or those with commercial insurance. Those without insurance or with high deductible plans may still face financial barriers, which is why the ASAP Act’s expansion of Medicare coverage is significant but only part of the solution.
Clinical Benefits and Treatment Implications
Earlier detection through blood biomarkers opens the door to earlier intervention. Research shows that when patients with Alzheimer’s biomarkers are identified early and treated with FDA-approved disease-modifying treatments, they can experience 30-60% slowing of cognitive decline compared to untreated individuals. This is not a cure, and it’s not a guarantee—outcomes vary by individual, by treatment, and by how early the intervention begins. But for a disease that has historically offered no way to slow progression once symptoms appear, the ability to delay decline by months or years can meaningfully extend a person’s period of independence and quality of life.
Current FDA-approved tests are recommended for adults age 55 and older who are experiencing cognitive symptoms or cognitive concerns. This is an important limitation: these tests are not recommended for asymptomatic screening of the general population at this time. The reason is straightforward—many people have Alzheimer’s biomarkers but never develop symptoms, and widespread screening could lead to unnecessary anxiety, treatment, and medicalization of normal aging. The clinical value of testing is highest for people who have noticed changes in their thinking or who have a family history of dementia and are concerned. As evidence accumulates about outcomes in asymptomatic populations and as new treatments become available, this guidance may evolve, but today’s recommendations reflect a thoughtful balance between early detection and avoiding overtreatment.
Federal Funding and Infrastructure Expansion
Congress’s approval of $100 million in new NIH funding for Alzheimer’s and dementia research signals renewed commitment to advancing the science. This funding supports laboratory research into new biomarkers, clinical trials of new treatments, and implementation studies examining how to scale up early detection in real-world settings. The specific allocation of $41.5 million to the CDC’s Building Our Largest Dementia Infrastructure (BOLD) Act is particularly noteworthy because it focuses on public health infrastructure—training community health workers, establishing dementia registries in states, and building capacity in underserved areas.
BOLD funding is especially important for rural and underserved communities, where access to specialty care and advanced diagnostics has traditionally been limited. By strengthening public health infrastructure, these funds aim to ensure that early detection and prevention efforts don’t become available only in affluent urban centers. For example, a BOLD-funded initiative might train primary care clinicians in a rural state to recognize cognitive symptoms, offer blood biomarker testing, and coordinate referral to appropriate treatments—eliminating the need for patients to travel hours to reach a memory specialist.
The Future of Alzheimer’s Prevention and Early Detection
The Alzheimer’s Association reports that the field is undergoing a fundamental shift from a symptomatic to a prevention-focused approach. Rather than waiting for a patient to report memory problems, researchers and clinicians are increasingly focused on identifying people with preclinical Alzheimer’s—those with biomarker evidence of disease but no symptoms yet—and offering interventions before cognitive decline begins. This shift is enabled by blood biomarkers, which make early identification practical and scalable.
Looking ahead, several trends will likely shape how these policy changes and new tests are implemented. Expanded screening could uncover millions of Americans with preclinical Alzheimer’s, driving increased demand for cognitive behavioral interventions, preventive medications, and monitoring. As more data emerges on which biomarkers most strongly predict future decline and which treatments are most effective for different groups, clinical practice will likely become more personalized. The next few years will be critical for determining how effectively these policy changes, new blood tests, and increased funding translate into better outcomes for patients and their families.
Conclusion
The policy changes coming through legislation like the ASAP Act, combined with FDA-approved blood biomarker tests and increased federal funding, are positioned to expand Alzheimer’s screening nationwide and fundamentally alter the trajectory of Alzheimer’s disease management. For the first time, Medicare beneficiaries may soon have efficient, affordable access to blood-based tests that can identify Alzheimer’s-related biological changes years before cognitive decline becomes apparent. The significance of this shift cannot be overstated: identifying at-risk individuals earlier opens a window of opportunity for early intervention and potentially significant slowing of cognitive decline.
If you are age 55 or older and have noticed changes in your thinking, memory, or cognition—or if you have a family history of dementia and are concerned—talk with your primary care doctor about whether Alzheimer’s biomarker testing is appropriate for you. Ask whether your health system uses blood-based tests and about the cost and coverage. As these policies take effect and testing becomes more widely available, earlier detection could become a cornerstone of dementia prevention and brain health across the country.
Frequently Asked Questions
Will blood biomarker tests be available at my regular doctor’s office?
This depends on your healthcare system’s adoption and whether your doctor has ordered these tests before. As Medicare coverage expands through the ASAP Act and as more primary care practices become familiar with blood biomarker testing, availability should increase. Talk to your doctor about whether these tests are available in your area.
If my blood biomarker test is positive, do I have Alzheimer’s disease?
A positive test means you have evidence of Alzheimer’s-related biological changes in your blood, but it does not mean you currently have Alzheimer’s disease or that you will definitely develop cognitive decline. Many people with positive biomarkers remain cognitively normal for years. A positive result indicates increased risk and may warrant discussion with your doctor about preventive interventions or closer monitoring, but it’s not a diagnosis of active disease.
Are blood biomarker tests covered by insurance?
Medicare coverage is expanding through efforts like the ASAP Act, and the CMS reimbursement rate is $130 per test. Coverage by commercial insurance and Medicaid varies by plan and state. Check with your insurance provider about your specific coverage. Even if insurance doesn’t cover the full cost, the test is relatively affordable compared to imaging-based diagnostics.
Who should be screened for Alzheimer’s biomarkers?
Current recommendations are for adults age 55 and older who are experiencing cognitive symptoms or have cognitive concerns, or who have a family history of dementia. These tests are not recommended for asymptomatic screening of the general population at this time, though this may change as evidence grows.
If I test positive for Alzheimer’s biomarkers, what happens next?
A positive test typically prompts discussion with your doctor about risk factors, lifestyle modifications (exercise, cognitive activity, cardiovascular health, sleep), and potentially preventive medications if you qualify. Your doctor may recommend follow-up cognitive testing or monitoring to track whether changes occur. Treatment options and recommendations vary based on individual circumstances.
How accurate are blood biomarker tests?
Blood biomarker tests carry a 97.9% negative predictive value, meaning if your test is negative, the probability of current Alzheimer’s-related biological changes is very low. Positive predictive value varies based on age, symptoms, and which biomarker is measured, but these tests have been validated as accurate aids in Alzheimer’s assessment.
